TEL AVIV, Israel, March 6, 2019 /PRNewswire/ -- Galmed
Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmedˮ or the "Company"), a
clinical-stage biopharmaceutical company focused on the development
of the liver targeted SCD1 modulator Aramchol, a once-daily, oral
therapy for the treatment of nonalcoholic steatohepatitis ("NASH")
and fibrosis, announced today that it will host a conference call
and webcast on Wednesday, March 13,
2018, to provide an update on current developments with
respect to its clinical programs for Aramchol™ and to discuss
financial results for the quarter and year ended December 31, 2018.
Conference Call & Webcast:
Wednesday, March 13th @
8:30am Eastern Time.
Within the US: 877-425-9470
Outside the US: 201-389-0878
From Israel: 1 809 406 247
Conference ID: 13687890
Webcast: http://public.viavid.com/index.php?id=133389
About Galmed Pharmaceuticals Ltd.
Galmed is a clinical-stage biopharmaceutical company focused on
the development of Aramchol, a first in class, novel, once-daily,
oral therapy for the treatment of NASH for variable populations.
Galmed recently announced top-line results of the ARREST Study, a
multicenter, randomized, double blind, placebo-controlled Phase
2b clinical study designed to
evaluate the efficacy and safety of Aramchol in subjects with NASH,
who are overweight or obese, and who are pre-diabetic or
type-II-diabetic. Galmed is currently preparing for an end of Phase
2b meeting with the FDA to discuss
the results of the ARREST Study and a Phase 3/4 study protocol,
with a view to initiating a Phase 3/4 clinical study of Aramchol in
2019.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-report-fourth-quarter-and-year-end-2018-financial-results-and-provide-business-update-on-wednesday-march-13-300807551.html
SOURCE Galmed Pharmaceuticals Ltd.